Table 1.

Association between miR-132 Expression and Clinicopathologic Features in Patients with Gastric Cancer

	Parameters	No. of Patients	Change in miR-132 Expressiona	p Valueb
Age (y)	<65	130	0.70 (0.23–1.39)	0.036
	≥65	71	0.40 (0.14–0.96)
Gender	male	153	0.63 (0.21–1.21)	0.300
	female	48	0.31 (0.14–1.36)
Location	upper third	14	0.48 (0.26–1.02)	0.426
	middle third	32	0.60 (0.25–2.05)
	lower third	113	0.70(0.17–1.29)
Gross type	extensive	42	0.41 (0.13–1.03)	0.571
	localized	29	0.47 (0.10–1.66)
	infiltrative	172	0.59 (0.19–1.22)
Size (maximal diameter)	<5 cm	89	0.87 (0.31–1.43)	0.001
	≥5 cm	112	0.39 (0.14–0.99)
Histological type	intestinal	89	0.89 (0.26–1.70)	0.003
	diffuse	112	0.46 (0.16–0.88)
Depth of invasion (pT)	T1, T2, T3	130	0.73 (0.24–1.42)	0.007
	T4	71	0.45 (0.14–0.84)
Lymph node status (pN)	N0, N1	94	0.57 (0.20–1.15)	0.732
	N2, N3	107	0.57 (0.18–1.36)
Lymph node metastasis	no	57	0.64 (0.20–1.25)	0.886
	yes	144	0.55 (0.18–1.24)
Lymphatic invasion	no	154	0.63 (0.22–1.26)	0.236
	yes	47	0.45 (0.11–1.01)
Venous invasion	no	193	0.60 (0.22–1.27)	0.002
	yes	8	0.09 (0.06–0.33)
Hematogenous metastasisc	no	181	0.64 (0.21–1.34)	0.022
	yes	20	0.32 (0.11–0.57)
Implantation metastasis	no	189	0.57 (0.18–1.24)	0.890
	yes	12	0.54 (0.22–1.49)
Pathological stage	I–IIIb	160	0.65 (0.22–1.35)	0.041
	IIIc and IV	41	0.32 (0.17–0.92)

^aMedian of relative expression, with 25th–75th percentile in parentheses.

^bMann-Whitney test (for two groups) or Kruskal-Wallis test (for more than two groups).

^cHepatic metastasis, pulmonary metastasis, bone metastasis, and brain metastasis occurrence before the operation or within 5 years after the operation.